{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:27:04Z","timestamp":1792801624729,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2008,10,31]],"date-time":"2008-10-31T00:00:00Z","timestamp":1225411200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurosci Behav Physi"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1007\/s11055-008-9077-3","type":"journal-article","created":{"date-parts":[[2008,10,30]],"date-time":"2008-10-30T06:51:04Z","timestamp":1225349464000},"page":"937-945","source":"Crossref","is-referenced-by-count":117,"title":["Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial)"],"prefix":"10.1007","volume":"38","author":[{"given":"I. V.","family":"Litvinenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. M.","family":"Odinak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. I.","family":"Mogil\u2019naya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Yu.","family":"Emelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,10,31]]},"reference":[{"key":"9077_CR1","first-page":"74","volume-title":"Extrapyramidal Diseases: Handbook of Diagnosis and Treatment","author":"Zh. M. Glozman","year":"2002","unstructured":"Zh. M. Glozman and O. S. Levin, \u201cMental disorders in extrapyramidal diseases,\u201d in: Extrapyramidal Diseases: Handbook of Diagnosis and Treatment [in Russian], V. N. Shtok, I. A. Ivanova-Smolenskaya, and O. S. Levin (eds.), MEDpress-Inform, Moscow (2002), pp. 74\u201386."},{"key":"9077_CR2","volume-title":"Parkinson's disease and Parkinson's Syndrome","author":"V. L. Golubev","year":"1999","unstructured":"V. L. Golubev, Ya. I. Levin, and A. M. Vein, Parkinson's disease and Parkinson's Syndrome [in Russian], MEDpress, Moscow (1999)."},{"key":"9077_CR3","unstructured":"O. S. Levin and N. A. Amosova, Psychotic Disorders in Parkinson's disease. Scientific-Practical Conference on Parkinson's Disease [in Russian], Moscow (1999), pp. 30\u201332."},{"issue":"10","key":"9077_CR4","first-page":"15","volume":"105","author":"O. S. Levin","year":"2005","unstructured":"O. S. Levin, \u201cEfficacy of Reminyl in dementia with Lewy bodies,\u201d Zh. Nevropatol. Psikhiat., 105, No. 10, 15\u201321 (2005).","journal-title":"Zh. Nevropatol. Psikhiat."},{"issue":"3","key":"9077_CR5","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/archneur.56.5.595","volume":"56","author":"D. Aarsland","year":"1999","unstructured":"D. Aarsland, J. P. Larsen, J. L. Cumming, et al., \u201cPrevalence and clinical correlates of psychotic symptoms in Parkinson's disease,\u201d Arch. Neurol., 56, No. 3, 595\u2013601 (1999).","journal-title":"Arch. Neurol."},{"issue":"6","key":"9077_CR6","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1212\/WNL.56.6.730","volume":"56","author":"D. Aarsland","year":"2001","unstructured":"D. Aarsland, K. Andersen, J. P. Larsen, et al., \u201cRisk of dementia in Parkinson's Disease: A community-based prospective study,\u201d Neurology, 56, No. 6, 730\u2013736 (2001).","journal-title":"Neurology"},{"issue":"10","key":"9077_CR7","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/gps.949","volume":"18","author":"D. Aarsland","year":"2003","unstructured":"D. Aarsland, M. Hutchinson, and J. P. Larsen, \u201cCognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia,\u201d Int. J. Geriat. Psychiat., 18, No. 10, 937\u2013941 (2003).","journal-title":"Int. J. Geriat. Psychiat."},{"issue":"6","key":"9077_CR8","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/1531-8249(200012)48:6<868::AID-ANA7>3.0.CO;2-0","volume":"48","author":"C. Ballard","year":"2000","unstructured":"C. Ballard, M. Piggott, and M. Johnson, \u201cDelusions associated with elevated muscarinic binding in dementia with Lewy bodies,\u201d Ann. Neurol., 48, No. 6, 868\u2013876 (2000).","journal-title":"Ann. Neurol."},{"issue":"23","key":"9077_CR9","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1001\/jama.282.23.2215","volume":"282","author":"S. R. Beach","year":"1999","unstructured":"S. R. Beach and R. Schulz, \u201cCaregiving as a risk factor for mortality: the Caregiver Health Effects Study,\u201d J. Amer. Med. Assoc., 282, No. 23, 2215\u20132219 (1999).","journal-title":"J. Amer. Med. Assoc."},{"issue":"12","key":"9077_CR10","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1001\/archneur.60.12.1745","volume":"60","author":"N. I. Bohnen","year":"2003","unstructured":"N. I. Bohnen, D. I. Kaufer, L. S. Ivanco, et al., \u201cCortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study,\u201d Arch Neurol., 60: No. 12, 1745\u20131748 (2003).","journal-title":"Arch Neurol."},{"issue":"2","key":"9077_CR11","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s00415-005-0971-0","volume":"253","author":"N. I. Bohnen","year":"2005","unstructured":"N. I. Bohnen, D. I. Kaufer, R. Hendrickson, et al., \u201cCognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia,\u201d J. Neurol., 253, No. 2, 242\u2013247 (2005).","journal-title":"J. Neurol."},{"issue":"3","key":"9077_CR12","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1017\/S0033291700029901","volume":"21","author":"J. L. Boyd","year":"1991","unstructured":"J. L. Boyd, C. A. Cruikshank, C. W. Kenn, et al., \u201cCognitive impairment and dementia in Parkinson's disease: a controlled study,\u201d Psychol. Med., 21, No. 3, 911\u2013921 (1991).","journal-title":"Psychol. Med."},{"issue":"5","key":"9077_CR13","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1185\/030079902125000813","volume":"18","author":"R. Bullock","year":"2002","unstructured":"R. Bullock and A. Cameron, \u201cRivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series,\u201d Curr. Med. Res. Opin., 18, No. 5, 258\u2013264 (2002).","journal-title":"Curr. Med. Res. Opin."},{"issue":"11","key":"9077_CR14","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.33588\/rn.3211.2000161","volume":"32","author":"M. J. Catalan-Alonso","year":"2001","unstructured":"M. J. Catalan-Alonso and J. Del Val, \u201cDopaminomimetic psychosis in Parkinson's disease: first symptom of early dementia?\u201d Rev. Neurol., 32, No. 11, 1085\u20131087 (2001).","journal-title":"Rev. Neurol."},{"issue":"12","key":"9077_CR15","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","volume":"44","author":"J. L. Cummings","year":"1994","unstructured":"J. L. Cummings, M. Mega, K. Gray, et al., \u201cThe Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia,\u201d Neurology, 44, No. 12, 2308\u20132314 (1994).","journal-title":"Neurology"},{"issue":"3","key":"9077_CR16","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1023\/A:1020736131907","volume":"22","author":"C. Cunha Da","year":"2002","unstructured":"C. Da Cunha, M. E. Angelucci, N. S. Canteras, et al., \u201cThe lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities,\u201d Cell Mol. Neurobiol., 22, No. 3, 227\u2013237 (2002).","journal-title":"Cell Mol. Neurobiol."},{"issue":"7","key":"9077_CR17","doi-asserted-by":"crossref","first-page":"691","DOI":"10.33588\/rn.3507.2002046","volume":"35","author":"E. Duran Ferreras","year":"2002","unstructured":"E. Duran Ferreras, J. Chacon, and J. A. Quintana, \u201cThe role of olanzapine in Parkinsonian dopaminergic psychosis,\u201d Rev. Neurol., 35, No. 7, 691\u2013696 (2002).","journal-title":"Rev. Neurol."},{"issue":"Supplement1","key":"9077_CR18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000074681","volume":"17","author":"K. R. Edwards","year":"2004","unstructured":"K. R. Edwards, L. Hershey, and L. Wray, \u201cEfficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis,\u201d Dement. Geriat. Cogn. Disord., 17, Supplement 1, 40\u201348 (2004).","journal-title":"Dement. Geriat. Cogn. Disord."},{"issue":"8","key":"9077_CR19","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.2105\/AJPH.84.8.1261","volume":"84","author":"R. L. Ernst","year":"1994","unstructured":"R. L. Ernst and J. W. Hay, \u201cThe US economic and social costs of Alzheimer's disease revisited,\u201d Amer. J. Public Health, 84, No. 8, 1261\u20131264 (1994).","journal-title":"Amer. J. Public Health"},{"issue":"1","key":"9077_CR20","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s100720200022","volume":"23","author":"G. Fabbrini","year":"2002","unstructured":"G. Fabbrini, P. Barbanti, C. Aurilia, et al., \u201cDonepezil in the treatment of hallucinations and delusions in Parkinson's disease,\u201d Neurol. Sci., 23, No. 1, 41\u201343 (2002).","journal-title":"Neurol. Sci."},{"issue":"7","key":"9077_CR21","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/brain\/123.4.733","volume":"123","author":"G. Fenelon","year":"2000","unstructured":"G. Fenelon, F. Mahieux, R. Huon, et al., \u201cHallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors,\u201d Brain, 123, No. 7, 733\u2013745 (2000).","journal-title":"Brain"},{"issue":"5","key":"9077_CR22","first-page":"434","volume":"63","author":"J. M. Graham","year":"1967","unstructured":"J. M. Graham, R. A. Grunewald, and H. J. Sagar, \u201cHallucinosis,\u201d J. Neurol. Neurosurg. Psychiat., 63, No. 5, 434\u2013440 (1967).","journal-title":"J. Neurol. Neurosurg. Psychiat."},{"issue":"7","key":"9077_CR23","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/gps.1339","volume":"20","author":"D. Grossi","year":"2005","unstructured":"D. Grossi, L. Trojano, and M. T. Pellecchia, \u201cFrontal dysfunction contributes to the genesis of hallucinations in non-demented Parkinsonian patients,\u201d Int. J. Geriat. Psychiat., 20, No. 7, 668\u2013673 (2005).","journal-title":"Int. J. Geriat. Psychiat."},{"issue":"6","key":"9077_CR24","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/brain\/awf134","volume":"125","author":"K. Ito","year":"2002","unstructured":"K. Ito, A. Nagano-Saito, T. Kato, et al., \u201cStriatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study,\u201d Brain, 125, No. 6, 1358\u20131365 (2002).","journal-title":"Brain"},{"issue":"1","key":"9077_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/gps.993","volume":"19","author":"I. Leroi","year":"2004","unstructured":"I. Leroi, J. Brandt, and S. G. Reich, \u201cRandomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease,\u201d Int. J. Geriat. Psychiat., 19, No. 1, 1\u20138 (2004).","journal-title":"Int. J. Geriat. Psychiat."},{"issue":"6","key":"9077_CR26","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1212\/01.wnl.0000203114.03976.b0","volume":"66","author":"T. Mori","year":"2006","unstructured":"T. Mori, M. Ikeda, and R. Fukuhara, \u201cCorrelation of visual hallucinations with occipital rCBF changes by donepezil in DLB,\u201d Neurology, 66, No. 6, 935\u2013937 (2006).","journal-title":"Neurology"},{"issue":"5","key":"9077_CR27","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s004150050364","volume":"246","author":"K. Okada","year":"1999","unstructured":"K. Okada, N. Suyama, H. Oguro, et al., \u201cMedication-induced hallucination and cerebral blood flow in Parkinson's disease,\u201d J. Neurol., 246, No. 5, 365\u2013368 (1999).","journal-title":"J. Neurol."},{"key":"9077_CR28","first-page":"66","volume-title":"An Essay on the Shaking Palsy","author":"J. Parkinson","year":"1817","unstructured":"J. Parkinson, An Essay on the Shaking Palsy, Sherwood, Neely and Jones, London (1817), p. 66."},{"issue":"2","key":"9077_CR29","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/00002093-199307020-00002","volume":"7","author":"E. Perry","year":"1993","unstructured":"E. Perry, D. Irving, J. M. Kerwin, et al., \u201cCholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease,\u201d Alzheimer. Dis. Assoc. Disord., 7, No. 2, 69\u201379 (1993).","journal-title":"Alzheimer. Dis. Assoc. Disord."},{"issue":"6","key":"9077_CR30","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/00002826-200211000-00002","volume":"25","author":"I. H. Richard","year":"2002","unstructured":"I. H. Richard, A. W. Justus, N. H. Greig, et al., \u201cWorsening of motor function and mood in a patient with Parkinson's disease after pharmacologic challenge with oral rivastigmine,\u201d Clin. Neuropharmacol., 25, No. 6, 296\u2013299 (2002).","journal-title":"Clin. Neuropharmacol."},{"issue":"Supplement1","key":"9077_CR31","first-page":"20","volume":"127","author":"M. Rosler","year":"2002","unstructured":"M. Rosler, \u201cThe efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia,\u201d Int. J. Clin. Pract., 127, Supplement 1, 20\u201336 (2002).","journal-title":"Int. J. Clin. Pract."},{"issue":"7","key":"9077_CR32","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1093\/brain\/awh177","volume":"127","author":"A. J. Saykin","year":"2004","unstructured":"A. J. Saykin, H. A. Wishart, and L. A. Rabin, \u201cCholinergic enhancement of frontal lobe activity in mild cognitive impairment,\u201d Brain, 127, No. 7, 1574\u20131583 (2004).","journal-title":"Brain"},{"issue":"2","key":"9077_CR33","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF02883326","volume":"19","author":"W. S. Shaw","year":"1997","unstructured":"W. S. Shaw, T. L. Patterson, and S. J. Semple, \u201cLongitudinal analysis of multiple indicators of health decline among spousal caregivers,\u201d Ann. Behav. Med., 19, No. 2, 101\u2013109 (1997).","journal-title":"Ann. Behav. Med."},{"issue":"9","key":"9077_CR34","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1001\/archneur.59.9.1415","volume":"59","author":"C. Summerfield","year":"2002","unstructured":"C. Summerfield, B. Gomez-Anson, E. Tolosa, et al., \u201cDementia in Parkinson's disease: a proton magnetic resonance spectroscopy study,\u201d Arch., Neurol., 59, No. 9, 1415\u20131420 (2002).","journal-title":"Arch., Neurol."},{"issue":"5","key":"9077_CR35","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1532-5415.1989.tb02233.x","volume":"37","author":"T. Sunderland","year":"1989","unstructured":"T. Sunderland, J. L. Hill, A. M. Mellow, et al., \u201cClock drawing in Alzheimer's disease: a novel measure of dementia severity,\u201d J. Amer. Geriat. Soc., 37, No. 5, 725\u2013729 (1989).","journal-title":"J. Amer. Geriat. Soc."},{"issue":"12","key":"9077_CR36","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1212\/WNL.54.12.2269","volume":"54","author":"P. N. Tariot","year":"2000","unstructured":"P. N. Tariot, P. R. Solomon, J. C. Morris, et al., \u201cA 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group,\u201d Neurol., 54, No. 12, 2269\u20132276 (2000).","journal-title":"Neurol."},{"issue":"12","key":"9077_CR37","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1212\/01.wnl.0000191565.11065.11","volume":"65","author":"E. Y. Uc","year":"2005","unstructured":"E. Y. Uc, M. Rizzo, and S. W. Anderson, \u201cVisual dysfunction in Parkinson disease without dementia,\u201d Neurology, 65, No. 12, 1907\u20131913 (2005).","journal-title":"Neurology"},{"key":"9077_CR38","unstructured":"C. H. Van Dyck, P. Tariot, M. Farlow, et al., \u201cMemantine\/donepezil dual-therapy is superior to placebo\/donepezil for treatment of moderate to severe Alzheimer's disease,\u201d in: Abstracts of the 6th International Conference on Alzheimer's Disease and Parkinson's Disease, Seville, Spain (2003), p. 491."},{"issue":"4","key":"9077_CR39","first-page":"165","volume":"149","author":"R. J. Marum Van","year":"2005","unstructured":"R. J. Van Marum and P. A. Jansen, \u201cIncreased risk of stroke during the use of olanzapine or risperidone in patients with dementia,\u201d Ned. Tijdschr. Geneeskd., 149, No. 4, 165\u2013167 (2005).","journal-title":"Ned. Tijdschr. Geneeskd."},{"issue":"1","key":"9077_CR40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1017\/S1355617703910022","volume":"9","author":"S. P. Woods","year":"2003","unstructured":"S. P. Woods and A. I. Troster, \u201cProdromal fontal\/executive dysfunction predicts incident dementia in Parkinson's disease,\u201d J. Int. Neuropsychol. Soc., 9, No. 1, 17\u201324 (2003).","journal-title":"J. Int. Neuropsychol. Soc."},{"issue":"3","key":"9077_CR41","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/archneur.60.3.337","volume":"60","author":"C. Zarow","year":"2003","unstructured":"C. Zarow, S. A. Lyness, J. A. Mortimer, and H. C. Chaul, \u201cNeuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer's and Parkinson's diseases,\u201d Arch. Neurol., 60, No. 3, 337\u2013341 (2003).","journal-title":"Arch. Neurol."},{"issue":"3","key":"9077_CR42","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1124\/mol.104.000299","volume":"66","author":"I. Zhang","year":"2004","unstructured":"I. Zhang, F. Zhou, and J. A. Dani, \u201cCholinergic drugs for Alzheimer's disease enhance in vitro dopamine release,\u201d Mol. Pharmacol., 66, No. 3, 538\u2013544 (2004).","journal-title":"Mol. Pharmacol."}],"container-title":["Neuroscience and Behavioral Physiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11055-008-9077-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11055-008-9077-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11055-008-9077-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T12:14:45Z","timestamp":1738498485000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11055-008-9077-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,31]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["9077"],"URL":"https:\/\/doi.org\/10.1007\/s11055-008-9077-3","relation":{},"ISSN":["0097-0549","1573-899X"],"issn-type":[{"value":"0097-0549","type":"print"},{"value":"1573-899X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,31]]}}}